Esprit completes $90 million series B financing round

By Elaine Rigoli

Tampa, Fla., Aug. 2 - Esprit Pharma has completed a series B funding round, raising $90,790,000 in financing from a group of venture capital and private equity investors.

Firms participating included existing investors New Enterprise Associates, Apax Partners, Inc., Domain Associates LLC and Montagu Newhall Global Partners plus new investors Oak Investment Partners and clients advised by Performance Equity Management.

Esprit is a niche-oriented pharmaceutical company located in East Brunswick, N.J.

Issuer:	Esprit Pharma
Issue:	Series B financing
Amount:	$90.79 million
Investors:	New Enterprise Associates, Apax Partners, Inc., Domain Associates LLC, Montagu Newhall Global Partners, Oak Investment Partners and clients advised by Performance Equity Management
Announcement date:	Aug. 2

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.